J&J/Critikon
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson divests its Critikon patient monitoring business to investor group led by Liberty Partners and Critikon management for undisclosed terms. Going private allows Tampa, Florida-based Critikon "to focus on our strength in vital signs monitoring, specifically non-invasive blood pressure detection and blood pressure cuffs, while improving the access to vital information for caregivers," President and CEO Gordie Nye states
You may also be interested in...
GE Medical Gains Access To DinaMap Via Critikon Purchase
GE Medical Systems' purchase of Critikon will allow it to integrate the Tampa, Florida-based firm's DinaMap non-invasive blood pressure software technology with GE's Dash line of patient monitors. The deal is expected to close by year-end.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.